The HLA molecules DQA1*0501/B1*0201 and DQA1*0301/B1*0302 share an extensive overlap in peptide binding specificity
about
sameAs
Mapping the Pareto optimal design space for a functionally deimmunized biotherapeutic candidateProtein deimmunization via structure-based design enables efficient epitope deletion at high mutational loadsNatural peptides selected by diabetogenic DQ8 and murine I-A(g7) molecules show common sequence specificity.Quantitative peptide binding motifs for 19 human and mouse MHC class I molecules derived using positional scanning combinatorial peptide libraries.A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approachFive HLA-DP molecules frequently expressed in the worldwide human population share a common HLA supertypic binding specificity.The immune recognition of gluten in coeliac disease.Identification of an I-Ed-restricted T-cell epitope of Escherichia coli outer membrane protein F.Specificity of peptide selection by antigen-presenting cells homozygous or heterozygous for expression of class II MHC molecules: The lack of competitionTrans heterodimer between two non-arthritis-associated HLA alleles can predispose to arthritis in humanized miceCD4+ T cell epitope identification: applications to allergy.Cell-surface MHC density profiling reveals instability of autoimmunity-associated HLA.The effect of the MHC locus on autoantibodies in type 1 diabetesStructure-based redesign of lysostaphin yields potent antistaphylococcal enzymes that evade immune cell surveillance.Intestinal T cell responses to gluten peptides are largely heterogeneous: implications for a peptide-based therapy in celiac disease.Divergent motifs but overlapping binding repertoires of six HLA-DQ molecules frequently expressed in the worldwide human population.Computationally optimized deimmunization libraries yield highly mutated enzymes with low immunogenicity and enhanced activity.Functional classification of class II human leukocyte antigen (HLA) molecules reveals seven different supertypes and a surprising degree of repertoire sharing across supertypesA deimmunised form of the ribotoxin, α-sarcin, lacking CD4+ T cell epitopes and its use as an immunotoxin warhead.Definition of CD4 Immunosignatures Associated with MTB.Interaction of allergens, major histocompatibility complex molecules, and T cell receptors: a 'ménage à trois' that opens new avenues for therapeutic intervention in type I allergy.Tuberculosis in the course of sarcoidosis treatment: is genotyping necessary for personalized therapy?Associations of human leukocyte antigens with autoimmune diseases: challenges in identifying the mechanism.CD74/DQA1 dimers predispose to the development of arthritis in humanized mice.A HLA-DRB supertype chart with potential overlapping peptide binding function.Functional recombinant MHC class II molecules and high-throughput peptide-binding assays.MHC-independent genetic regulation of liver damage in a mouse model of autoimmune hepatocellular injury.Characterizing the binding motifs of 11 common human HLA-DP and HLA-DQ molecules using NNAlign.HLA Class II molecules on haplotypes associated with type 1 diabetes exhibit similar patterns of binding affinities for coxsackievirus P2C peptides.
P2860
Q28543006-77B566E3-EE48-411F-BB43-31CC03E4580CQ30371474-F903F8D5-53B9-4E18-AB9A-715D8C3B4FEAQ33220897-DDF5EEFF-3A4F-43C8-A146-04C2DA0EA330Q33316579-6B4D228D-3844-441D-A737-20C4CFF082D0Q33326976-91944FAA-3F4B-4F4B-9294-F737E31E3308Q33530024-82EB886E-993D-4484-A805-F7753940F43FQ34423420-D46AB91D-1301-4AB6-8848-126163F01EEDQ34756687-6E4567E8-111B-4B94-AC0C-67C981C13552Q34982899-00A5FAC7-C065-4CB9-A302-3D33F9D1A19DQ35019501-7A2D7CE5-F4EA-4EAA-9975-C0982EBD6837Q35129657-47C94E49-A53F-4CD9-B88B-AD432BDA3CA2Q35242376-689FAC52-9A0B-43F4-8C19-5E7E327B0251Q35726979-A57B3752-7982-4938-9538-5727146095BBQ35751036-CC6E0DF6-B625-48D5-9DDA-76DC60262020Q35835769-5288D034-29FC-4CC9-BAB8-EE40058BE7DBQ35839141-39640325-7A00-4D0B-B664-13374CE17F0DQ36399908-71F86FDC-E648-4B0E-BBDC-418E8D61B580Q36766285-81A70BCE-213B-49A7-929F-4DF872EBA1A5Q37367958-14D4DAB1-B258-4FCD-BBCD-DBA48363E8C5Q37672921-F839F686-2AE7-4896-A75A-01A15C0FF747Q37859218-4569133E-9292-4FB3-8542-C7ACD871B5E5Q38096028-A5980274-CA37-4517-86B8-32190518E07EQ38569872-43165ECF-A23E-4FE0-8B72-4DA3E483D224Q40366569-40205372-7F93-4B3F-9713-76137AF7E637Q42139951-0A2C520E-036A-4BA1-9198-60535E4F2A69Q43118417-36033C1A-FE28-4F4D-8E98-19CF35C40888Q45254403-83F35850-A35A-4B37-857C-2371552E34FFQ51419330-51CDC843-EDAE-45F7-88FE-1953000FAD7BQ51987940-FC7A30CA-8692-48BB-852F-43C4FFCAA6A9
P2860
The HLA molecules DQA1*0501/B1*0201 and DQA1*0301/B1*0302 share an extensive overlap in peptide binding specificity
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
The HLA molecules DQA1*0501/B1 ...... in peptide binding specificity
@ast
The HLA molecules DQA1*0501/B1 ...... in peptide binding specificity
@en
The HLA molecules DQA1*0501/B1 ...... in peptide binding specificity
@nl
type
label
The HLA molecules DQA1*0501/B1 ...... in peptide binding specificity
@ast
The HLA molecules DQA1*0501/B1 ...... in peptide binding specificity
@en
The HLA molecules DQA1*0501/B1 ...... in peptide binding specificity
@nl
prefLabel
The HLA molecules DQA1*0501/B1 ...... in peptide binding specificity
@ast
The HLA molecules DQA1*0501/B1 ...... in peptide binding specificity
@en
The HLA molecules DQA1*0501/B1 ...... in peptide binding specificity
@nl
P2093
P3181
P1476
The HLA molecules DQA1*0501/B1 ...... in peptide binding specificity
@en
P2093
John Sidney
Marie-France del Guercio
Scott Southwood
P304
P3181
P356
10.4049/JIMMUNOL.169.9.5098
P407
P577
2002-11-01T00:00:00Z